Role of BMPRII Mutants in the Pathogenesis of Pulmonary Hypertension
Role of BMPRII Mutants in the Pathogenesis of Pulmonary Hypertension
批准号:
7433181
负责人:
Akiko Hata
金额:
$35.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2010-06-30
关键词:
AffectApoptosisApoptosis InhibitorApoptoticBIRC4 geneBMP7 geneBiologicalBloodBlood VesselsC-terminalCell CountCell DeathCell ProliferationCell physiologyCellsCharacteristicsDataDevelopmentDown-RegulationEmbryoEtiologyFailureFamilyFibroblastsGenesGerm-Line MutationGoalsHumanHypertrophyLigand BindingLigand Binding DomainLungMaintenanceMammalian CellMapsMedialMediatingMediator of activation proteinMolecularMusMutationNeuronsNormal CellPathogenesisPatientsPhenotypePhosphotransferasesPhysiologicalPlayProcessProgressive DiseaseProtein-Serine-Threonine KinasesProteinsPulmonary HypertensionPulmonary Vascular ResistancePulmonary artery structureRegulationResearch PersonnelResistanceRight ventricular structureRoleSequence HomologySignal PathwaySignal TransductionSmooth MuscleSmooth Muscle MyocytesStructureTailTestingTransforming Growth FactorsTransgenic MiceVentricularbone morphogenetic protein receptor type IIcaspase-3cell growthcytochrome cextracellularin vivomembermortalitymutantneuronal cell death inducible putative kinaseprimary pulmonary hypertensionprogramspulmonary arterial hypertensionreceptorresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pulmonary hypertension (PH) is characterized by an increase in pulmonary vascular resistance that impedes ejection of blood by the right ventricle, leading to right ventricular failure. Primary PH (PPH) is a rare but progressive disease with a mortality of 30 percent over 4 years. Recently germline mutations in bone morphogenetic protein receptor type II (BMPRII), a member of the transforming growth factor ¿ (TGF ¿) receptor family, have been found in over 50 percent of familial PPH patients and in 30 percent of sporadic cases of PPH. Mutations have been found in the extracellular, ligand binding, and cytoplasmic serine/threonine kinase domains, as well as the long carboxyl-terminal region (tail domain). The long-term objective of this application is to understand the molecular mechanism(s) by which BMPRII mutations contribute to the pathogenesis of pulmonary arterial hypertension. We found that BMPs promote, apoptotic cell death in normal human pulmonary artery smooth muscle cells (PASMCs). BMP-mediated apoptosis in PASMCs is associated with activation of caspases-3, -8, and -9, cytochrome c release, and downregulation of Bcl-2. PASMCs expressing mutant forms of BMPRII identified in PPH patients are resistant to BMP- mediated apoptosis. The specific hypothesis to be tested is that mutation(s) in the BMPRII disrupts BMP- mediated apoptosis in PASMCs, which is required for maintenance of normal cell number in the pulmonary vasculature. In Specific Aim 1, we will characterize the apoptotic-signaling pathway mediated by BMP7 in PASMCs. In Specific Aim 2, we will characterize the biological activities of BMPRII mutants found in PPH and generate transgenic mice expressing a BMPRII tail domain truncation mutant gene in smooth muscle to examine the role of this mutant BMPRII in vivo. We recently discovered that neuronal cell death-inducible putative kinase (NIPK) interacts with the tail domain of BMPRII in mammalian cells. NIPK contains a ser/thr kinase-like domain. Therefore, in Specific Aim 3 we will focus on the functional role of the interaction between NIPK and the tail domain of BMPRII in the regulation of BMP-mediated signaling pathways. These studies will elucidate the mechanism of BMP-dependent apoptosis in PASMCs and the role of the tail domain of the BMPRII in the regulation of the BMP signaling pathway, which is of fundamental importance to understanding the molecular mechanisms underlying the pathogenesis of pulmonary hypertension.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the structural insights into the BMP receptor mutations in PAH
-
批准号:10659947
-
项目类别:
-
资助金额:$80.52万
-
财政年份:2023
-
负责人:Akiko Hata
-
依托单位:
Molecular pathogenesis of pulmonary arterial hypertension
-
批准号:10211271
-
项目类别:
-
资助金额:$80.37万
-
财政年份:2021
-
负责人:Akiko Hata
-
依托单位:
Molecular pathogenesis of pulmonary arterial hypertension
-
批准号:10400195
-
项目类别:
-
资助金额:$79.57万
-
财政年份:2021
-
负责人:Akiko Hata
-
依托单位:
Molecular pathogenesis of pulmonary arterial hypertension
-
批准号:10560621
-
项目类别:
-
资助金额:$77.95万
-
财政年份:2021
-
负责人:Akiko Hata
-
依托单位:
Identification of a novel modulator of Pulmonary Artery Hypertension
-
批准号:9282758
-
项目类别:
-
资助金额:$63.09万
-
财政年份:2016
-
负责人:Akiko Hata
-
依托单位:
Identification of a novel modulator of Pulmonary Artery Hypertension
-
批准号:9088922
-
项目类别:
-
资助金额:$67.06万
-
财政年份:2016
-
负责人:Akiko Hata
-
依托单位:
Role of the PDGF signaling pathway in pulmonary artery hypertension
-
批准号:8461453
-
项目类别:
-
资助金额:$37.37万
-
财政年份:2013
-
负责人:Akiko Hata
-
依托单位:
Role of the PDGF signaling pathway in pulmonary artery hypertension
-
批准号:8714040
-
项目类别:
-
资助金额:$38.67万
-
财政年份:2013
-
负责人:Akiko Hata
-
依托单位:
Role of miRNAs in Vascular Physiology
-
批准号:8266380
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2009
-
负责人:Akiko Hata
-
依托单位:
Role of miRNAs in Vascular Physiology
-
批准号:8304423
-
项目类别:
-
资助金额:$24.36万
-
财政年份:2009
-
负责人:Akiko Hata
-
依托单位:
Role of miRNAs in Vascular Physiology
-
批准号:7653575
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2009
-
负责人:Akiko Hata
-
依托单位:
Role of miRNAs in Vascular Physiology
-
批准号:8064747
-
项目类别:
-
资助金额:$15.89万
-
财政年份:2009
-
负责人:Akiko Hata
-
依托单位:
Role of miRNAs in Vascular Physiology
-
批准号:7847445
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2009
-
负责人:Akiko Hata
-
依托单位:
Role of BMPRII Mutants in the Pathogenesis of Pulmonary Hypertension
-
批准号:7256245
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2006
-
负责人:Akiko Hata
-
依托单位:
Role of BMPRII Mutants in the Pathogenesis of Pulmonary Hypertension
-
批准号:7147201
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2006
-
负责人:Akiko Hata
-
依托单位:
Role of BMPRII Mutants in the Pathogenesis of Pulmonary Hypertension
-
批准号:7626762
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2006
-
负责人:Akiko Hata
-
依托单位:
Mechanisms of TGFB Signal Transduction
-
批准号:6679446
-
项目类别:
-
资助金额:$28.53万
-
财政年份:2003
-
负责人:Akiko Hata
-
依托单位:
Mechanisms of TGFB Signal Transduction
-
批准号:7056161
-
项目类别:
-
资助金额:$27.86万
-
财政年份:2003
-
负责人:Akiko Hata
-
依托单位:
Mechanisms of TGFB Signal Transduction
-
批准号:7237989
-
项目类别:
-
资助金额:$27.05万
-
财政年份:2003
-
负责人:Akiko Hata
-
依托单位:
Mechanisms of TGFB Signal Transduction
-
批准号:6772530
-
项目类别:
-
资助金额:$28.53万
-
财政年份:2003
-
负责人:Akiko Hata
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: